Activity Description
This course covers early intervention strategies for geographic atrophy and presbyopia, highlighting the importance of timely diagnosis, newer therapeutics that slow disease progression, and an overview of currently available pharmacological treatment options for presbyopia, including recently FDA-approved agents and guidance on patient selection.
Accreditation Statements
Sponsored by
Axiom Ophthalmic, LLC is a COPE-Approved Administrator.
This activity, COPE Activity Number 133117, is accredited by COPE for continuing education for optometrists. This course is approved for 1.0 hours of CE.
Course # 104786-TD
Activity # 133117
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Release Date: 7-31-2026
Expiration Date: 07-31-2027
Target Audience
This accredited educational activity is designed for optometrists.
Grant Support Statement
This activity is supported by an unrestricted educational grant from Apellis, Carl Zeiss Meditec, and Tenpoint Therapeutics.
Faculty
Steven Ferrucci, OD, FAAO
- Program Chair
- Chief of Optometry
- Sepulveda VA Medical Center
- Professor, Southern California
- College of Optometry
- Marshall B. Ketchum University
- Fullerton, California
Joshua Davidson, OD, FAAO, FSLS
- Williamson Eye Center
- Baton Rouge, Louisiana
Selina McGee, OD, FAAO
- Founder & Chief Optometrist
- BeSpoke Vision
- Edmond, Oklahoma
Mary Beth Yackey, OD
- Cincinnati Eye Institute
- Cincinnati, Ohio
Program Description
This course covers early intervention strategies for geographic atrophy and presbyopia, highlighting the importance of timely diagnosis, newer therapeutics that slow disease progression, and an overview of currently available pharmacological treatment options for presbyopia, including recently FDA-approved agents and guidance on patient selection.
Expert Faculty
- Steven Ferrucci, OD, FAAO
- Joshua Davidson, OD, FAAO, FSLS
- Selina McGee, OD, FAAO
- Mary Beth Yackey, OD
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Summarize the prevalence of early-stage presbyopia and the incidence and risk factors for the development of intermediate dry AMD and GA and the impact on functional and anatomical outcomes (Knowledge)
- Compare the mechanisms of action for current and emerging pharmaceutical treatments of early-stage presbyopia based on published clinical trial data and real-world reports, and identify ideal patient candidates for the treatment options (Knowledge, Competence, Performance)
- Integrate multimodal diagnostic strategies, including OCT-A, for early diagnosis and classification of dry AMD/GA (Competence, Performance)
- Assess safety and efficacy data for new and emerging intermediate dry AMD and GA treatments, including complement inhibition and multiwavelength photobiomodulation, understand the importance of earlier intervention, and initiate early collaborative management with retina specialists who are utilizing these therapies (Knowledge, Competence, performance)
Credit Designation
This enduring educational activity is eligible for COPE-accredited continuing education credit.
Credit Hours: 0.5
